(3aR,4R,5R,6S,6aS)-6-amino-5-fluoro-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-ol | 1423769-15-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (3aR,4R,5R,6S,6aS)-6-amino-5-fluoro-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-ol
• CAS: 1423769-15-6
• 化学式: C₈H₁₄FNO₃
• 分子量: 191.202
• InChiKey: GESWXPBPQMEHJX-ULQPCXBYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  64.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (3aR,4R,5R,6S,6aS)-6-amino-5-fluoro-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-ol 在 potassium tert-butylate 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 生成 ethyl 2-[[(3aS,4R,5R,6S,6aS)-5-fluoro-2,2-dimethyl-6-(phenylmethoxycarbonylamino)-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]oxy]acetate
  参考文献：
  名称：

  Synthesis and biological evaluation of cyclopentyl-triazolol-pyrimidine (CPTP) based P2Y12 antagonists

  摘要：

  In this Letter we describe SAR investigation on the cyclopentyl-triazolol-pyrimidine scaffold in pursuit of new oral P2Y(12) inhibitors. Different synthetic routes were developed for variations at the cyclopentyl core. Optimization finally led to compound 2d which was advanced into preclinical development based on better potency and safety profile in comparison to ticagrelor. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.11.055
• 作为产物：
  描述：

  (3aS,4R,5R,6S,6aS)-5-fluoro-2,2-dimethyl-4-phenylmethoxy-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-6-amine 在 氢气 、 palladium(II) hydroxide 作用下， 以 甲醇 为溶剂， 生成 (3aR,4R,5R,6S,6aS)-6-amino-5-fluoro-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-ol
  参考文献：
  名称：

  Synthesis and biological evaluation of cyclopentyl-triazolol-pyrimidine (CPTP) based P2Y12 antagonists

  摘要：

  In this Letter we describe SAR investigation on the cyclopentyl-triazolol-pyrimidine scaffold in pursuit of new oral P2Y(12) inhibitors. Different synthetic routes were developed for variations at the cyclopentyl core. Optimization finally led to compound 2d which was advanced into preclinical development based on better potency and safety profile in comparison to ticagrelor. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.11.055

文献信息

• [EN] TRIAZOLOPYRIMIDINE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF<br/>[FR] DÉRIVÉ DE TRIAZOLOPYRIMIDINE, PROCÉDÉ DE PRÉPARATION ET UTILISATION
  申请人：SHANGHAI HENGRUI PHARM CO LTD

  公开号：WO2013023511A1

  公开（公告）日：2013-02-21

  本发明涉及三唑并嘧啶类衍生物、其制备方法及其用途。具体而言，本发明涉及一种通式(I)所示的三唑并嘧啶类衍生物，以及它们作为治疗剂特别是作为P2Y12受体拮抗剂的用途，其中通式(I)中的各取代基的定义与说明书中的定义相同。